PT  - JOURNAL ARTICLE
AU  - Nowak, Marta
AU  - Jabbar, Faiz
AU  - Rodewald, Ann-Katrin
AU  - Gneo, Luciana
AU  - Tomasevic, Tijana
AU  - Harkin, Andrea
AU  - Iveson, Tim
AU  - Saunders, Mark
AU  - Kerr, Rachel
AU  - Oein, Karin
AU  - Maka, Noori
AU  - Hay, Jennifer
AU  - Edwards, Joanne
AU  - Tomlinson, Ian
AU  - Sansom, Owen
AU  - Kelly, Caroline
AU  - Easton, Alistair
AU  - Domingo, Enric
AU - TransSCOT group
AU  - Koelzer, Viktor H
AU  - Church, David N
TI  - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
AID  - 10.1101/2023.12.18.23300137
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.18.23300137
4099  - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300137.short
4100  - http://medrxiv.org/content/early/2023/12/18/2023.12.18.23300137.full
AB  - Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRC). Automation of this would facilitate precision medicine, particularly if it provided information on likely aetiology. We developed AIMMer, an AI-based method for determination of MMR protein expression at single cell level in routine pathology samples. We applied it to over 2,000 colorectal cancers (CRC) from the SCOT clinical trial, which compared 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy (FOLFOX or CAPOX). Benchmarking of AIMMeR against pathologist ground truth MMR calls revealed AUROC of 0.98, and positive predictive value (PPV) greater than 95% for the commonest pa[ern of somatic MMRd, and for retained MMR expression. Analysis of CRC recurrence confirmed the prognostic value of MMRd in oxaliplatin-treated patients. While MMRd did not predict differential benefit from chemotherapy duration, it correlated with difference in clinical outcome by chemotherapy regimen (PInteraction=0.04). AIMMeR holds promise to reduce pathologist workflow and streamline clinical diagnostics in CRC.Competing Interest StatementDNC has participated in advisory boards for MSD and has received research funding on behalf of the TransSCOT consortium from HalioDx for analyses independent of this study. VHK has served as an invited speaker on behalf of Indica Labs, and has received project-based research funding from The Image Analysis Group and Roche outside of the submitted work. All other authors declared no competing interestsFunding StatementThis study was funded by the Oxford NIHR Comprehensive Biomedical Research Centre (BRC), a Cancer Research UK (CRUK) Advanced Clinician Scientist Fellowship (C26642/A27963) to DC, CRUK award A25142 to the CRUK Glasgow Centre. V.H.K. acknowledges funding by the Promedica Foundation (F-87701-41-01). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for patient recruitment and sample collection in the SCOT trial was approved centrally and at all recruiting centres. Ethical approval for anonymized tumour molecular analysis was granted by Oxfordshire Research Ethics Committee B (Approval No 05\Q1605\66).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets pertaining to the SCOT trial used during the current study are available from the TransSCOT collaboration on reasonable request. Applications for analysis of TransSCOT samples are welcome and should be addressed to JH: Jennifer.Hay{at}glasgow.ac.uk